Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-10-26Clinical Trial Update: Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors [Phase 1, Phase 2]
Phase 1/2 trial evaluating aibrutinib combination therapy in selected gastrointestinal and genitourinary tumors has completed with results p…
-
CLINICAL_TRIALS trial_result · 2022-10-06Clinical Trial Update: Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma [Phase 2]
Phase 2 trial update evaluating a tailored immunotherapy approach with nivolumab in metastatic or advanced renal cell carcinoma.
-
FDA approval · 2022-09-22FDA Approved: INLYTA — Supplemental Application (U.S. Pharmaceuticals)
The FDA approved a supplemental application for INLYTA (axitinib) filed by U.S. Pharmaceuticals, updating the drug’s labeling.
-
CLINICAL_TRIALS trial_result · 2022-09-21Clinical Trial Update: REduced Frequency ImmuNE Checkpoint Inhibition in Cancers [Phase 2]
Phase 2 clinical trial update on reduced-frequency immune checkpoint inhibition in cancers including renal cell carcinoma and melanoma.
-
CLINICAL_TRIALS trial_result · 2022-09-02Clinical Trial Update: Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed [Phase 2]
A Phase 2 trial update reports results from testing cabozantinib, crizotinib, savolitinib, and sunitinib in patients with locally advanced o…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-08-23Clinical Trial Update: The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma [Phase 1, Phase 2]
A trial update for CAPER, a Phase 1/2 study evaluating cyclophosphamide with pembrolizumab in metastatic renal cell carcinoma.
-
CLINICAL_TRIALS trial_result · 2022-08-11Clinical Trial Update: Using Virtual Reality (VR) Models for Preoperative Planning [NA]
Completed clinical trial evaluating the use of virtual reality models for preoperative planning in kidney cancer (renal cell carcinoma); res…
-
CLINICAL_TRIALS trial_result · 2022-07-19Clinical Trial Update: Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery [Phase 3]
This update reports results from a Phase 3 trial of pazopanib hydrochloride in patients with metastatic renal cell carcinoma who have no evi…
-
CLINICAL_TRIALS trial_result · 2022-07-01Clinical Trial Update: Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors [Phase 2]
Phase 2 trial evaluating famitinib plus anti-PD1 therapy for advanced renal cell carcinoma, urothelial carcinoma, and gynecologic cancers su…
-
CLINICAL_TRIALS trial_result · 2022-06-07Clinical Trial Update: Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer [Phase 2]
Phase 2 trial evaluating trebananib with or without other targeted therapies for advanced renal cell carcinoma has completed with results po…
-
FDA approval · 2022-06-07FDA Approved: SORAFENIB — Original Application (Dr.Reddys Laboratories Inc)
FDA approves the original application for a generic sorafenib product from Dr. Reddy's Laboratories Inc, expanding access to the cancer drug…
-
CLINICAL_TRIALS trial_result · 2022-05-18Clinical Trial Update: Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) [Phase 1, Phase 2]
Phase 1/2 trial assessing safety and tolerability of pembrolizumab combined with pegylated interferon alfa-2b or with ipilimumab in advanced…
-
CLINICAL_TRIALS trial_result · 2022-05-11Clinical Trial Update: Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) [Phase 2]
Phase 2 study of pembrolizumab monotherapy in locally advanced or metastatic renal cell carcinoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-05-10Clinical Trial Update: A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) [Phase 2]
Phase 2 clinical trial update for INCMGA00012 in selected solid tumors, with completed status and results posted.
-
CLINICAL_TRIALS trial_result · 2022-05-10Clinical Trial Update: A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)
A retrospective medical record review of first-line sunitinib schedules and outcomes in metastatic renal cell carcinoma patients in Latin Am…
-
CLINICAL_TRIALS trial_result · 2022-05-03Clinical Trial Update: A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line [Phase 3]
Phase 3 trial comparing Web-mediated follow-up kidneyPRO vs standard follow-up in first-line axitinib/pembrolizumab for metastatic renal cel…
-
CLINICAL_TRIALS trial_result · 2022-05-03Clinical Trial Update: Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma [Phase 2]
Phase 2 trial evaluating nivolumab plus stereotactic body radiotherapy in II-III line metastatic renal cell carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2022-04-26Clinical Trial Update: A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma [Phase 3]
Phase 3 trial comparing nivolumab plus cabozantinib to sunitinib in patients with previously untreated advanced or metastatic renal cell car…
-
CLINICAL_TRIALS research · 2022-04-25Clinical Trial Update: Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) [Phase 2]
A Phase 2 trial (OMNIVORE) is evaluating optimized management of nivolumab based on patient response in advanced renal cell carcinoma; the s…
-
FDA approval · 2022-04-13FDA Approved: ALYMSYS — Original Application (Amneal Pharmaceuticals LLC)
FDA approves ALYMSYS as a biosimilar to bevacizumab (bevaczizumab-maly) from Amneal Pharmaceuticals LLC under an original Biologics License …
-
FDA approval · 2022-04-11FDA Approved: SUNITINIB MALATE — Original Application (Dr.Reddys Laboratories Inc)
FDA approved a generic version of sunitinib malate (SUNITINIB MALATE) from Dr. Reddy's Laboratories Inc under Original Application.
-
CLINICAL_TRIALS trial_result · 2022-04-05Clinical Trial Update: Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer [Phase 2]
Phase 2 trial of pazopanib hydrochloride in stage IV renal cell carcinoma completed; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-03-16Clinical Trial Update: Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery [Phase 2]
A Phase 2 trial evaluating pazopanib hydrochloride with or without ascorbic acid in metastatic or unresectable clear cell renal cell carcino…
-
CLINICAL_TRIALS trial_result · 2022-03-11Clinical Trial Update: M8891 First in Human in Solid Tumors [Phase 1]
Phase 1 first-in-human trial of M8891 in solid tumors has been terminated; results were posted.
-
CLINICAL_TRIALS trial_result · 2022-03-10Clinical Trial Update: Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma [Phase 1, Phase 2]
Clinical trial evaluating pazopanib in combination with interferon alfa-2a in advanced renal cell carcinoma across Phase 1 and Phase 2, comp…